TP53 Polyclonal Antibody (E-AB-52130)
For research use only.
| Verified Samples |
Verified Samples in WB: 293T |
| Dilution | WB 1:500-1:2000 |
| Isotype | IgG |
| Host | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Clonality | Polyclonal |
| Immunogen | Fusion protein of human TP53 |
| Abbre | TP53 |
| Synonyms | Antigen NY-CO-13, BCC7, Cellular tumor antigen p53, FLJ92943, LFS1, Mutant tumor protein 53, P53, Phosphoprotein p53, TRP53, Tp53, Transformation related protein 53, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, p53, p53 tumor suppressor |
| Swissprot | |
| Calculated MW | 44 kDa |
| Observed MW |
Refer to figures
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Cytoplasm, Cytoplasm, Nucleus, Nucleus>PML body, Endoplasmic reticulum, Interaction with BANP promotes nuclear localization, Recruited into PML bodies together with CHEK2, Nucleus, Cytoplasm, Localized in both nucleus and cytoplasm in most cells, In some cells, forms foci in the nucleus that are different from nucleoli, Nucleus, Cytoplasm, Localized in the nucleus in most cells but found in the cytoplasm in some cells, Nucleus, Cytoplasm, Localized mainly in the nucleus with minor staining in the cytoplasm, Nucleus, Cytoplasm, Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4 and Nucleus, Cytoplasm, Predominantly nuclear but translocates to the cytoplasm following cell stress. |
| Concentration | 1 mg/mL |
| Buffer | Phosphate buffered solution, pH 7.4, containing 0.05% stabilizer and 50% glycerol. |
| Purification Method | Antigen affinity purification |
| Research Areas | Cancer, Cell Biology, Epigenetics and Nuclear Signaling |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended. |
| background | TP53,also named as P53 and NY-CO-13,belongs to the p53 family. It has 9 isoforms. In SDS-Page,the MW is about 53kd. TP53 acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. It is involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. The antibody reacts specifically with 53 kDa protein. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
